Use of proteomics for validation of the isolation process of clotting factor IX from human plasma

Journal of Proteomics

Volumn 73, Issue 3, 2010, Pages 678-688

  Clifton, James ^a   Huang, Feilei ^a,b   Gaso Sokac, Dajana ^c   Brilliant, Kate ^a,b   Hixson, Douglas ^a,b   Josic, Djuro ^a,b,c  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

Author keywords

Clotting factor IX; Fractionation; Human plasma; Proteomics; Vitamin K dependent clotting factors

Indexed keywords

ANION EXCHANGE RESIN; BLOOD CLOTTING FACTOR 9; HEPARIN; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G; INHIBITOR PROTEIN; INTER ALPHA INHIBITOR PROTEIN; PROTEINASE; UNCLASSIFIED DRUG; VITRONECTIN;

AFFINITY CHROMATOGRAPHY; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; HUMAN; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN ISOLATION; PROTEOMICS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

ANION EXCHANGE RESINS; BLOOD COAGULATION FACTORS; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, AGAROSE; DEAE-DEXTRAN; FACTOR IX; HEMOFILTRATION; HEPARIN; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PLASMA; PROTEOMICS; SOLID PHASE EXTRACTION; VALIDATION STUDIES AS TOPIC;

EID: 72149086924     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2009.09.020     Document Type: Article

References (38)

1. DiScipio R.G., Hermodson M.A., Yates S.G., and Davie E.W. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor) and protein S. Biochemistry 16 (1977) 698-706
2. Choo K.H., Gould K.G., Rees D.J., and Brownlee G.G. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature 299 (1982) 178-180
3. Josephson C.D., and Abshire T.C. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease. Best Pract Res Clin Haematol 19 (2006) 35-49
4. Manucci P.M. Treatment of hemophilia: recombinant factors only? No. J Thromb Haemost 1 (2003) 216-217
5. Sheffield W.P., Mamdani A., Hortelano G., Gataiance S., Eltringham-Smith L., Begbie M.E., et al. Effect of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 126 (2004) 565-573
6. Josic D., Hoffer L., and Buchacher A. Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor Protein C. J Chromatogr B 790 (2003) 183-197
7. Anderson, NL, Anderson, NG. The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-867. Corrections 2003; 2: 50.
8. Hoffer L., Schwinn H., and Josic D. Production of highly purified clotting factor IX by a combination of different chromatographic methods. J Chromatogr A 844 (1999) 119-128
9. Hrinda M.E., Huang C., Tarr G.C., Weeks R., Feldman F., and Schreiber A.B. Preclinical studies of monoclonal antibody purified factor IX, Mononine ™. Semin Hematol 28 Suppl 6 (1991) 6-14
10. Kasper C.K. Concentrate safety and efficacy. Haemophilia 8 (2002) 161-165
11. Josic D., Brown M.K., Huang F., Lim Y.-P., Rucevic M., Clifton J.G., and Hixson D. Proteomic characterization of inter-alpha inhibitor proteins from human plasma. Proteomics 6 (2006) 2874-2885
12. Kovac S., Yang X., Huang F., Hixson D., and Josic D. Proteomics as a tool for optimization of human plasma protein separation. J Chromatogr A 1194 (2008) 38-47
13. Yang X., Clifton J., Huang F., Kovac S., Hixson D.C., and Josic D. Proteomic analysis for process development and control of therapeutic protein separation from human plasma. Electrophoresis 30 (2009) 1185-1193
14. Josic D., and Kovac S. Application of proteomics in biotechnology - microbial proteomics. J Biotechnol 3 (2008) 496-509
15. Liumbruno G., D'Amici G.M., Grazzini G., and Zolla L. Transfusion medicine in the era of proteomics. J. Proteomics 71 (2008) 34-45
16. Lion N., and Tissot J.D. Application of proteomics to hematology: the revolution is starting. Expert Rev Proteomics 5 (2008) 375-379
17. Brigulla M., Thiele T., Scharf C., Breitner-Ruddock S., Venz S., Völker U., et al. Proteomics as a tool for assessment of therapeutics in transfusion medicine: evaluation of prothrombin complex concentrates. Transfusion 46 (2006) 377-385
18. Clifton J.G., Huang F., Kovac S., Yang X., Hixson D.C., and Josic D. Proteomic Characterization of Plasma-derived Clotting Factor VIII - von Willebrand Factor Concentrates. Electrophoresis 30 (2009) 10.1002/elps.200900270
19. In: Brummelhius H.G.J., and in Curlin J.M. (Eds). Methods of plasma protein fractionation (1980), Academic Press, London 117-128
20. Hoffer L., Schwinn H., Biesert L., and Josic D. Improved virus safety and purity of a chromatographically produced Factor IX concentrate by nanofiltration. J Chromatogr B 669 (1995) 187-196
21. Eng J., McCormack A.L., and Yates III Y.R. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 5 (1994) 976-989
22. Elias J.E., and Gygi S.P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 4 (2007) 207-214
23. Lawson E.L., Clifton J.G., Huang F., Li X., Hixson D.C., and Josic D. Use of magnetic beads with immobilized monoclonal antibodies for isolation of highly pure plasma membranes. Electrophoresis 27 (2006) 2747-2758
24. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., Khainovski N., Pallai S., Dey S., Daniels S., Purkayastha S., Juhasz P., Martin S., Bartlet-Jones M., He F., Jacobson A., and Pappin D.J. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3 (2004) 1154-1169
25. Clifton J.G., Li X., Reutter W., and Josic D. Comparative proteomics of rat liver and Morris hepatome 7777 plasma membranes. J Chromatogr B 849 (2007) 293-301
26. Burnouf T. Modern plasma fractionation. Transf Med Rev 21 (2007) 101-117
27. Grupta P., and Lee K.H. Genomics and proteomics in process development: opportunities and challenges. Trends Biotechnol 25 (2007) 324-330
28. Blostein M., Cuerquis J., and Galipeau J. Galectin 3-binding protein is a potential contaminant of recombinantly produced factor IX. Haemophilia 13 (2007) 701-706
29. Josic D., Kannicht C., Löster K., Pock K., Iberer G., and Buchacher A. Vitronectin in clotting factor IX concentrates. Haemophilia 7 (2001) 250-257
30. Fortis F., Guerrier L., Areces L.B., Antonioli P., Hayes T., Carrick K., Hammond D., Boschetti E., and Righetti P.G. A new approach for the detection and identification of protein impurities using combinatorial solid phase ligand libraries. J Proteome Res 5 (2006) 2577-2585
31. Fenaille F., Groseil C., Ramon C., Riandé, Siret L., Chtourou S., and Bihoreau N. Mass spectrometric characterization of plasma-derived coagulation factor VII. Glycoconjugate J 25 (2008) 827-842
32. Chevreux G., Tilly N., Faid V., Ramon C., Groseil C., Riande S., Andre M., Scohyes J.-M., Bihoreau N., and Siret L. Structural characterization of plasma-derived coagulation factor IX using mass spectrometry. Proc Plasma Product Biotechnol Meeting (2009) 101
33. Klukowska A., Laguna P., Svirin P., and Vdovin V. Efficacy and safety of OCTANYNE F in children with haemophilia B. Haemophilia 14 (2008) 531-538
34. Burnouf T., Michalski C., Goudemand M., and Huart J.J. Properties of highly purified human plasma factor IX:C therapeutic concentrate prepared by conventional chromatography. Vox Sang 57 (1989) 225-232
35. Mizon C., Héron A., Capon C., Sautière P., Michalski C., Sesboüé R., and Mizon R. Human pre-alpha-inhibitor: isolation from by-product of industrial plasma fractionation and structural analysis of its H3 heavy chain. J Chromatogr B 692 (1997) 281-291
36. Di Scipio R., Kurachi K., and Davie E.W. Activation of human factor IX (Christmas factor). J Clin Invest 61 (1978) 1528-1538
37. Begbie M.E., Mamdani A., Gataiance S., Eltringham-Smith L.J., Bhakta V., Hortelano G., and Sheffield W.P. An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice. Thromb Haemost 94 (2005) 1138-1147
38. Pock K., Buchacher A., Rizzi A., and Josic D. Characterization of clotting factor IX in plasma-derived preparations by electrophoretic techniques. J Chromatogr A 921 (2001) 57-69